Bifilact-BILS® (BIFILACT-BILS®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBifidobacteria bifidum + Lactobacillus plantarumBifidobacteria bifidum + Lactobacillus plantarum
Similar drugsTo uncover
  • Bifilact-BILS®
    capsules inwards 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Florin Forte
    capsules inwards 
    PARTNER, CJSC     Russia
    • Dosage form: & nbsptoapsules
    Composition:

    One capsule (dose) of the drug contains:

    Active components:

    not less than 108 living bacteria strain Lactobacillus plantarum 8P-A3;

    not less than 107 living bacteria strain Lactobacillus acidophilus TO3W24;

    not less than 107 living bacteria strain Bifidobacterium bifidum 1.

    Excipients: kaolin (E559) - 40.0 mg, magnesium stearate - 2.5 mg, components of the protective environment of drying (gelatin, sucrose (sugar), milk).

    Capsules, hard gelatin

    Capsule composition: body and lid - titanium dioxide (E171); gelatin.

    Note

    Composition of protective drying medium (per 1 liter of medium): gelatin - from 1,5 to 3%, sucrose (sugar) - from 5 to 20%, milk powder - from 8 to 25%, water to 1000 ml.

    Description:

    Hard gelatin capsules No. 2 in white, opaque, cylindrical with hemispherical ends, consisting of two parts (body and lid). The surface of the capsules is smooth, without damage and visible air and mechanical inclusions.

    The contents of the capsules are a dry powder of beige or whitish-gray color with a specific odor.

    Pharmacotherapeutic group:Eubiotic
    ATX: & nbsp

    A.07.F.A   Antidiarrhoeal preparations of biological origin regulating the balance of intestinal microflora

    Pharmacodynamics:

    Characteristics of the preparation

    The preparation is a mixture of the microbial mass of living, antagonistically active bacteria strains Lactobacillus plantarum 8P-A3, Lactobacillus acidophilus TO3W24 and Bifidobacterium bifidum 1 (Lyophilised culture in medium supplemented with sucrose gelatin protective-lactic drying medium) and excipients, packed in hard gelatin capsules 1 dose.

    Pharmacological properties

    The therapeutic effect of the drug due to their content of live lactobacilli and bifidobacteria, which possess antagonistic activity against a wide range of pathogenic and conditionally pathogenic microorganisms reduced qualitative and quantitative composition of intestinal microflora, normalize digestive and intestinal protective function, activate metabolism, enhance non-specific resistance organism.

    While taking the drug showed a significant increase in the number of bifidobacteria and lactobacilli as well as the disappearance or reduction of clinical symptoms characteristic of dysbiosis gastrointestinal tract.

    Indications:

    Treatment of diseases of the gastrointestinal tract of various etiologies in persons aged 18 to 60:

    - dysbacteriosis of the intestine, which arose as a result of prolonged antibacterial, hormonal, radiation and other therapy, while staying in extreme conditions;

    - intestinal dysbiosis against the background of acute intestinal infections or food toxic infections, as well as in convalescents after acute intestinal infections or foodborne toxic infections;

    - dysbacteriosis of the intestine in infectious and allergic diseases;

    - dysbacteriosis of the intestine, arising against a background of acute and chronic diseases of the gastrointestinal tract;

    - other diseases, accompanied by a violation of the normoflora of the intestine with a deficiency of lacto- and bifidobacteria.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Age to 18 years (due to the lack of data from clinical studies).

    Carefully:

    Before using the drug, you should consult your doctor.

    Pregnancy and lactation:

    The safety of Bifilact-BILS® during pregnancy and during breastfeeding during controlled clinical trials has not been investigated.

    Dosing and Administration:

    The drug is administered orally 30 minutes before meals or 1.5 hours after meals, with plenty of water or milk at room temperature.

    It is recommended to use Bifilact-BILS® 2 capsules 3 times a day. The course of treatment 2-4 weeks.

    If necessary, the course of treatment can be repeated 2-3 times.

    Side effects:

    Side effect of the drug during clinical trials is not established.

    In individuals with altered reactivity, allergic reactions to the drug components may develop.

    If side effects occur that are not mentioned in the instructions, you should contact your doctor.

    Overdose:

    Cases of overdose are not registered.

    Interaction:

    Not installed.

    Special instructions:

    The preparation with the broken integrity of the primary packaging (cans), with indistinct marking, is not suitable for use.

    It is not recommended to use the drug simultaneously with alcohol and hot drinks (above 40 ° C), due to a decrease in its effectiveness.

    The content of sucrose (sugar) and milk in the preparation is insignificant and does not exceed 0.1 grain units (XE) in a single dose.

    Effect on the ability to drive transp. cf. and fur:

    No information.

    Form release / dosage:Capsules, one dose.
    Packaging:

    For 40 capsules in a polymer jar with a screw cap with a silica gel insert.

    One bank in a pack of cardboard together with instructions for use.

    Storage conditions:

    In the dark place at a temperature of 2 to 8 ° C.

    Keep out of the reach of children.

    Transportation conditions

    At a temperature of 2 to 8 ° C.

    Shelf life:

    18 months Do not use after the expiration date printed on the package.

    After opening the package, the shelf life of the drug in a tightly closed jar should not exceed 30 days when stored at a temperature of 2 to 25 ° C.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003575
    Date of registration:19.04.2016
    Expiration Date:19.04.2021
    The owner of the registration certificate:MICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
    Manufacturer: & nbsp
    Representation: & nbspMICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
    Information update date: & nbsp16.02.2017
    Illustrated instructions
      Instructions
      Up